Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This has been running so hot the last few days I think it needs a day to cool off before the next move higher. I am a buyer.
Right you are. Happy to finally be in a cannabis stock at a good price. I personally missed the boat a long time ago.
EMHTF is a great chance to get in on a cannabis stock for those who missed the boat in the past few years.
EMHTF is about to go bullistic! Volume coming in.
This is definitely moving higher. I like it.
EMHTF is about to make a monster move higher.....target $6 to $7 is my gut feeling here.
ONCS...1.60's by afternoon. Time to take down 1.68. I think a nice pop at the close might do it.
Piper raises price target on Oncosec to $5 today. Good PISCES dat at SITC and Oncosec will break the three dollar ceiling set last year and likely make a run to $5.
As PISCES interim data release gets closer it will be harder to keep a lid on the share price.
Jeff, the MM's can't hold Oncosec down forever.
The CT order is for the collaboration and drug supply agreement for the TNBC trial to start next month, same as the last one for melanoma trial....no big deal. Check out exhibit 10.5 on the 10-Q filed on June 13, 2018. At the end of the CT filing it names the TNBC trial as what this relates to.
Oncosec on the move today. Lots to look forward to in the 2nd half of 2018.
50,000 share buy at 12:39 today. This drop is a buying opportunity. TNBC will start in August as well as other trials. BMY could throw a curve ball at the market and sponsor their combo trial with Oncosec.
You are correct dangerM. That is the same reposted article from Nature. I must have had a brain lapse. The direction that Oncosec is headed sounds exactly where this article is pointing to. Oncosec market disruption coming in the near future. Time for the market to wake up to Oncosec. We are building up to it in the second half of this year. The updates listed the other day are very reassuring that things will start to move along at a quicker pace.
Merck partnering in Head and Neck will be their 3rd collaboration agreement with Oncosec.
Bristol Myers' Opdivo in combo with Oncosec in neoadjuvant melanoma means they are getting on board as well finally.....a very good sign.
The multi-gene construct to be announced soon will utilize the latest Oncosec generator and applicators and hopefully take the market by surprise.
Oncosec is setting up for a very strong end of year with PISCES data to be released in the fall. If the results are stellar like the SITC results last year, 2019 will be explosive for the company. Multiple licensing deals will be struck. Oncosec will increase significantly in market cap and hopefully entertain a buyout offer.
hschlauch, your thoughts on this published article when you have a chance as it relates to Oncosec. Thanks! https://www.ucsf.edu/news/2018/06/410911/immune-profile-successful-cancer-immunotherapy-discovered?utm_source=ucsf_tw&utm_medium=tw&utm_campaign=2018_cancer_immunotherapy_prediction&utm_term=
As well as Head and Neck trial. Bristol getting in on the action in neoadjuvant melanoma...hopefully with cash upfront because this is not stated to be an IST like H&N trial.
Oncosec TNBC combo study with Merck set to start in August. https://clinicaltrials.gov/ct2/show/NCT03567720?term=Oncosec&rank=4
PISCES interim data was prematurely expected at ASCO.....simply too soon to present data there. Now 21 recruitment sites are enrolling patients for PISCES. We will most likely get interim data at SITC in November. Full enrollment is expected by 3rd quarter which means data will probably not be the full 23 patients in the first stage of the trial. Oncosec needs only a few patients to respond in the first stage of this simon minimax 2 stage trial to initiate the second stage of the trial with an additional 25 patients. When the first person was enrolled in December, Oncosec later gave the impression that the patient was having a positive response.....they were very excited about the trial start. If the interim data is good, then Oncosec will seek guidance from the FDA on fast-track approval. I think the idea is that they could initiate an early approval at the point they meet the 30% or greater threshold of responders....which would be a total of 16 patients out of 48. If they had outstanding results with 16 responders out of the first 23 patients in the first stage they would already have met the total responder numbers and could seek an early approval before stage 2 begins....that might be expecting pie in the sky though. Most likely it will take full enrollment of 48 patients and complete data next year for an approval by end of 2019.....commercialization in 2020.
Oncosec is set to begin releasing updates on trials soon including TNBC combo, Head and Neck triplet combo, adjuvant melanoma,.....IND filing for the multi-gene construct....which will enroll next year. PISCES data later this year will be stellar in my opinion.
have you "dud" your DD? I have done mine and Oncosec has a strong future pipeline.
Point72, Venbio, Nexthera, Millenium, Vanguard......large stakeholders anticipating solid PISCES data this year. Oncosec represents strong value right now with an explosive end-of-year catalyst. Oncosec milestones list still has PISCES interim data slated for 2018. There may have been a misconception by the market that the "trial in progress" poster at ASCO was supposed to be interim data release.....not so.....and shares dropped. Buying opportuniy for LONGS.
Couldn't agree with you more hschlauch. Complete disruption when the multi-gene construct gets under way next year. This year melanoma and PISCES data are just the tip of the iceberg. The market is completely underestimating what is happening at Oncosec Medical. I for one am very happy to remain a long-term shareholder.
I'll have 2 drinks to that! Long and Strong ONCS!
Seller volume drying up now. This will move back up very soon when we have some trial updates for TNBC and Head and Neck as well as Melanoma neo-adjuvant combo. These additional trials will likely be partnered with Merck as well. 2nd Half of 2018 is going to be stellar for Oncosec.
My thoughts on lung cancer were that maybe Oncosec would go for the systemic affect, probably not electroporating the lungs directly. My curiousity promted a message to Adil Daud and he was kind enough to reply about the potential in the lung cancer market. He believes it would make sense, but would have to develop the tech. This is something down the line.....maybe if melanoma and TNBC prove successful. I am really looking forward to the announcement of the PIIM candidate to see where the technology Oncosec has been working on is headed next. The collaboration with Avacta with affimers looks very interesting.
Obviously melanoma has been the main focus for Oncosec and PISCES will bring the platform validation with good data that leads to an approved therapy. After that first approval I think it will be game on regarding pipeline expansion. If there is a market worth going after I think Merck will be interested. Merck just bought Viralytics and I believe they will be snatching up Oncosec as well after more validation this year. No more huge acquisitions and wasted billions, smaller innovative tech is where they are building assets now.
Lung cancer is a huge market for Merck so I think they might consider trying a combo study with Oncosec in the future in that tumor type. Oncosec does have lung cancer on their list of tumor targets along with melanoma on their website besides TNBC, RCC, Head and Neck, bladder and gastric. When they unveil the next generation of "go anywhere devices" we may hear more about future plans for lung cancer. Just speculation of course. Would be fantastic if they did go after lung cancer.
The new CEO was brought in to guide Oncosec in the right direction going forward. The second half of 2018 should get a little more interesting.
-Melanoma data (PISCES)
-TNBC combo trial start
-Head and Neck triplet combo trial start
-Melanoma (neo-adjuvant) combo trial start
-PIIM IND filing
-file for ATMP classification in Europe
...lots to look forward to. Merck entering onto another collaboration with Oncosec in TNBC is a good sign in my opinion even before PISCES data release. That is confidence in my book. I wouldn't be surprised if Merck is involved in every one of these additional trials to be announced upcoming.
The next generation of the immunopulse platform will be able to reach more tumor types. I have been wondering if Oncosec could go after lung cancer. Would that be an indication suitable for electroporation? That would be a huge market to go after and Merck would surely be interested in that.
NSCLC is going to be huge for Merck. A combo study with immunopulse would be huge for Oncosec.
Oncosec will likely announce full enrollment in PISCES first cohort of patients at ASCO. Recent stock options for Dan O' Connor may have been the ones based on PISCES enrollment status. This means PISCES data is imminent this year....we will see at ASCO Meeting.
Vanguard, Point72, and Venbio are probably very happy to pick up more shares with this selloff. In the next few months I would bet Tute ownership will eclipse 50% of ONCS shares before PISCES data is released. I will be adding as well.
Todays price drop is just another opportunity for Tutes to swallow up more of the oustanding share count, less retail will be holding this when data is released later in the year.....people will be scrambling to buy shares at much higher prices.
Market was expecting patient data, but "Trials in Progress" it seems are about general information sharing. We will have to wait a bit longer for Oncosec to get enough patient data together to present at a conference such as SITC, or maybe another conference sooner. 21 sites are open and enrolling patients, so when they do present it should be for the entire first cohort of patients, 23 in all. Major Tute buying recently is banking on Oncosec presenting positive data when they do release it. My bet is they will succeed.
You are correct, but that doesn't mean the market is correct. We will see some data at ASCO on PISCES trial. The fate of Oncosec stock rests on the data. Excellent data will move the share price much higher. I would expect complete primary data for PISCES later this year at SITC. That is a ways off, so impatient investors may be selling now to buy back in if they belive the shares will drift lower. I take it as an opportunity to buy shares at a discount.
Oncosec and Merck will enter into a deep financial agreement when PISCES data is released.....either a buyout or a licensing deal.
O'Connor specifically said that the recent equity raise was to fund the TNBC phase II trial...no surprise there at all....maybe the market has forgotten about that. This is a bottom right now and Merck will be the buyer of Oncosec when PISCES results are released as well as TNBC data. 2018 or 2019....it will happen if the results in these trials are good....or at the very least Merck would do a substantial licensing deal with Oncosec and expand the pipeline even more....lung cancer combo would be excellent opportunity for both companies.
They will get these indications because if there is the possibility of similar CR's like in melanoma, then their TNBC combo will be best-in-class.
Might take full data in the TNBC pilot study to secure a partnership if nothing is secured yet. Oncosec has enrolled up to 8 patients so far. I think they will report complete data this year with probably 5 patients receiving Opdivo or other anti-pd1 drug. 10 patients total including monotherapy patients.
Solid data in the PISCES trial for Oncosec will solidify an FDA approval and that will validate their science and vindicate management. Only looking better and better for Oncosec this year. Preliminary data for TNBC looks promising too, so Big Pharma has something else to think about, not just melanoma when considereing the prospects for Oncosec. A share price spike on solid PISCES data this year may have ONCS running like CPXX right into a buyout.
I would say Oncosec is more like CPXX, going from below $3 to $30 on a buyout. Steve Cohen of Point72 Asset Management saw the early bargain in CPXX....now he sees the same bargain in Oncosec Medical. Until yesterday Point72 was Oncosec's largest holder. More 13G's coming soon.
Oncosec presents an incredible investing opportunity with PISCES trial and upcoming TNBC trial with partnering to be announced soon. Those who missed the boat after SITC get another chance before things progress further in 2018.
Oncosec is looking good. Recruitment sites are going full force, 21 sites up and running now. It is within reason that Oncosec will present data on at least 10 patients at ASCO. More news on TNBC partnering should hit soon. 8 of 10 payients are enrolled presently, so I would think later in the year, maybe SITC Oncosec will release full data on the pilot study plus the Opdivo dosed patients.